Cargando…

Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study

BACKGROUND: Hodgkin lymphoma (HL) is an uncommon B cell lymphoma. We assessed the global, regional, and national burden of HL from 1990 to 2017, by gender, age, and social-demographic index (SDI). METHODS: Data on HL, including incidence, mortality, and disability adjusted life-years (DALY), from 19...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Linghui, Deng, Yujiao, Li, Na, Zheng, Yi, Tian, Tian, Zhai, Zhen, Yang, Si, Hao, Qian, Wu, Ying, Song, Dingli, Zhang, Dai, Lyu, Jun, Dai, Zhijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805485/
https://www.ncbi.nlm.nih.gov/pubmed/31640759
http://dx.doi.org/10.1186/s13045-019-0799-1
_version_ 1783461396108804096
author Zhou, Linghui
Deng, Yujiao
Li, Na
Zheng, Yi
Tian, Tian
Zhai, Zhen
Yang, Si
Hao, Qian
Wu, Ying
Song, Dingli
Zhang, Dai
Lyu, Jun
Dai, Zhijun
author_facet Zhou, Linghui
Deng, Yujiao
Li, Na
Zheng, Yi
Tian, Tian
Zhai, Zhen
Yang, Si
Hao, Qian
Wu, Ying
Song, Dingli
Zhang, Dai
Lyu, Jun
Dai, Zhijun
author_sort Zhou, Linghui
collection PubMed
description BACKGROUND: Hodgkin lymphoma (HL) is an uncommon B cell lymphoma. We assessed the global, regional, and national burden of HL from 1990 to 2017, by gender, age, and social-demographic index (SDI). METHODS: Data on HL, including incidence, mortality, and disability adjusted life-years (DALY), from 1990 to 2017 were obtained from the 2017 Global Burden of Disease study. Estimated annual percentage changes (EAPCs) were calculated to assess incidence rate, mortality, and DALY trends. RESULTS: HL incidences increased by 38.66%, from 72,937 in 1990 to 101,133 in 2017, while the age-standardized incidence rate (ASIR) was relatively stable. ASIR decreased in the low SDI regions (EAPC = − 2.58; 95% CI, from − 2.66 to − 2.49) and was stable in the other four SDI regions. Incidence showed a bimodal distribution with peak values in patients aged 20–39 years and patients aged 60 years or higher. The number of death cases and DALYs were stable. The age-standardized death rate decreased by 2.36% (95% CI, from − 2.43% to − 2.30%) per year. The annual age-standardized DALY rate decreased by 2.29% (95% CI, from − 2.36% to − 2.21%). The incidence and mortality in male subjects was higher than that in female subjects. The incidence in male and female subjects aged 15–30 years old was close, whereas the biggest difference existed in patients aged < 10 years old and 45–75 years old between genders. CONCLUSION: Globally, incidence of HL was stable, while mortality and DALY rate of HL had been decreasing from 1990 to 2017. Compared with lower and decreasing ASIR in the low SDI region, ASIR in the high SDI region was always high, indicating the need for HL treatment improvement and the establishment of more targeted and specific strategies in high SDI countries to reduce the incidence of HL.
format Online
Article
Text
id pubmed-6805485
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68054852019-10-24 Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study Zhou, Linghui Deng, Yujiao Li, Na Zheng, Yi Tian, Tian Zhai, Zhen Yang, Si Hao, Qian Wu, Ying Song, Dingli Zhang, Dai Lyu, Jun Dai, Zhijun J Hematol Oncol Research BACKGROUND: Hodgkin lymphoma (HL) is an uncommon B cell lymphoma. We assessed the global, regional, and national burden of HL from 1990 to 2017, by gender, age, and social-demographic index (SDI). METHODS: Data on HL, including incidence, mortality, and disability adjusted life-years (DALY), from 1990 to 2017 were obtained from the 2017 Global Burden of Disease study. Estimated annual percentage changes (EAPCs) were calculated to assess incidence rate, mortality, and DALY trends. RESULTS: HL incidences increased by 38.66%, from 72,937 in 1990 to 101,133 in 2017, while the age-standardized incidence rate (ASIR) was relatively stable. ASIR decreased in the low SDI regions (EAPC = − 2.58; 95% CI, from − 2.66 to − 2.49) and was stable in the other four SDI regions. Incidence showed a bimodal distribution with peak values in patients aged 20–39 years and patients aged 60 years or higher. The number of death cases and DALYs were stable. The age-standardized death rate decreased by 2.36% (95% CI, from − 2.43% to − 2.30%) per year. The annual age-standardized DALY rate decreased by 2.29% (95% CI, from − 2.36% to − 2.21%). The incidence and mortality in male subjects was higher than that in female subjects. The incidence in male and female subjects aged 15–30 years old was close, whereas the biggest difference existed in patients aged < 10 years old and 45–75 years old between genders. CONCLUSION: Globally, incidence of HL was stable, while mortality and DALY rate of HL had been decreasing from 1990 to 2017. Compared with lower and decreasing ASIR in the low SDI region, ASIR in the high SDI region was always high, indicating the need for HL treatment improvement and the establishment of more targeted and specific strategies in high SDI countries to reduce the incidence of HL. BioMed Central 2019-10-22 /pmc/articles/PMC6805485/ /pubmed/31640759 http://dx.doi.org/10.1186/s13045-019-0799-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhou, Linghui
Deng, Yujiao
Li, Na
Zheng, Yi
Tian, Tian
Zhai, Zhen
Yang, Si
Hao, Qian
Wu, Ying
Song, Dingli
Zhang, Dai
Lyu, Jun
Dai, Zhijun
Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study
title Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study
title_full Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study
title_fullStr Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study
title_full_unstemmed Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study
title_short Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study
title_sort global, regional, and national burden of hodgkin lymphoma from 1990 to 2017: estimates from the 2017 global burden of disease study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805485/
https://www.ncbi.nlm.nih.gov/pubmed/31640759
http://dx.doi.org/10.1186/s13045-019-0799-1
work_keys_str_mv AT zhoulinghui globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT dengyujiao globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT lina globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT zhengyi globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT tiantian globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT zhaizhen globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT yangsi globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT haoqian globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT wuying globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT songdingli globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT zhangdai globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT lyujun globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy
AT daizhijun globalregionalandnationalburdenofhodgkinlymphomafrom1990to2017estimatesfromthe2017globalburdenofdiseasestudy